Grekas D, Syrganis C, Romtsou S, Makris P, Tsakiris D A, Tourkantonis A
First Medical Department, University of Thessaloniki, AHEPA Hospital, Greece.
Life Support Syst. 1985;3 Suppl 1:409-13.
The study is a comparison of two successive HD sessions on each patient. 60 min prior to the first session a placebo was administered orally, while to the second session 500 mg ticlopidine. Arterial blood samples for leucocyte and platelet counts, C3 complement, blood gases, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) measurement were taken before and 15, 30, 60, 120, 240 min during each HD session. Platelet aggregation (ADP 1 microM/ml) was also carried out pre and post-dialysis. It is suggested that ticlopidine: 1) prevents HD-induced complement activation and related phenomena, 2) normalize the increased plasma levels of platelet markers 3) inhibits the ADP-induced platelet aggregation.
该研究是对每位患者进行的两次连续血液透析治疗的对比。在第一次治疗前60分钟口服安慰剂，而在第二次治疗前口服500毫克噻氯匹定。在每次血液透析治疗前以及治疗期间的15、30、60、120、240分钟采集动脉血样本，用于检测白细胞和血小板计数、C3补体、血气、β-血小板球蛋白（β-TG）和血小板第4因子（PF-4）。透析前后还进行了血小板聚集试验（ADP 1微摩尔/毫升）。研究表明，噻氯匹定：1）可预防血液透析引起的补体激活及相关现象；2）使升高的血小板标志物血浆水平恢复正常；3）抑制ADP诱导的血小板聚集。
